2403 SIDNEY STREET, PITTSBURGH, PA
Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis - Positive Discussion on Path Forward for Registrational Program -
Reports Financial Results for the First Quarter 2026 and Provides Business Update
Annual Report to Security Holders
Investor Presentation
Advancing Zervimesine for DLB Psychosis - A Potential First Treatment
Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Material disclosure
Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload